Significance
The immune system normally produces antibodies against pathogens and avoids making antibodies against self-proteins. In some individuals, antibodies against self-proteins (autoantibodies) are made and can cause debilitating disease, but the reasons for this failure of self-tolerance are not known. The experiments described test the following hypothesis linking viral infections and production of autoantibodies: A B cell whose immunoglobulin receptor recognizes a self-membrane protein can capture that protein from the membrane of a virus-infected cell and simultaneously cocapture viral proteins; fragments of the viral protein can then be presented to antiviral T cells and qualify for the positive signals for proliferation and antibody production known as T-cell help. We observed this phenomenon in vitro and in vivo.
Keywords: tolerance, autoantibodies, antigen capture, antigen presentation, influenza
Abstract
Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with autoimmune central nervous system diseases like acute disseminated encephalomyelitis (ADEM). For ADEM, it is speculated that a preceding infection is the trigger of the autoimmune response, but the mechanism connecting the infection to the production of MOG antibodies remains a mystery. We reasoned that the ability of B cells to capture cognate antigen from cell membranes, along with small quantities of coexpressed “bystander” antigens, might enable B-cell escape from tolerance. We tested this hypothesis using influenza hemagglutinin as a model viral antigen and transgenic, MOG-specific B cells. Using flow cytometry and live and fixed cell microscopy, we show that MOG-specific B cells take up large amounts of MOG from cell membranes. Uptake of the antigen from the membrane leads to a strong activation of the capturing B cell. When influenza hemagglutinin is also present in the membrane of the target cell, it can be cocaptured with MOG by MOG-specific B cells via the B-cell receptor. Hemagglutinin and MOG are both presented to T cells, which in turn are activated and proliferate. As a consequence, MOG-specific B cells get help from hemagglutinin-specific T cells to produce anti-MOG antibodies. In vivo, the transfer of MOG-specific B cells into recipient mice after the cocapture of MOG and hemagglutinin leads to the production of class-switched anti-MOG antibodies, dependent on the presence of hemagglutinin-specific T cells. This mechanism offers a link between infection and autoimmunity.
An association between infections and autoimmunity has long been observed in clinical practice. Examples of this association are the onset of Guillain–Barré syndrome after intestinal Campylobacter infections and acute demyelinating encephalomyelitis (ADEM) following respiratory infections. Possible explanations for this connection between autoimmunity and infection include molecular mimicry between the infectious agent and the autoantigen and bystander activation of preexisting autoreactive immune cells. Although the molecular mimicry hypothesis is well supported for Guillain–Barré syndrome (1), the mechanisms leading to autoimmunity in other diseases are not understood. Among the most important suspected viral triggers of ADEM is influenza virus infection (2). It is also known that pediatric patients with ADEM especially mount a humoral immune response against myelin oligodendrocyte glycoprotein (MOG) (3). The mechnism through which the viral infection leads to the production of autoantibodies is unknown.
An important checkpoint for the avoidance of autoantibody production is the destruction of autoreactive B cells in the bone marrow (4). Unlike the case of T-cell selection in the thymus, where the transcriptional regulator AIRE ensures the expression of otherwise tissue-specific antigens (5), the set of antigens expressed in the bone marrow is limited, meaning that B cells whose Ig antigen receptors (B-cell receptor, BCR) recognize self-antigens restricted to other tissues can escape this selection and populate the periphery. Normally this does not lead to autoimmunity, because active production of antibodies requires T-cell help (6). This takes place in secondary lymphoid organs and involves extensive physical contact with a helper T-cell whose antigen receptor (T-cell receptor, TCR) recognizes a peptide displayed on the B cell’s major histocompatibility complex (MHC) class II molecules. Efficient negative T-cell selection in the thymus therefore also safeguards against the production of autoantibodies. If a B cell that recognizes a self-antigen is artificially enabled to obtain T-cell help, for example by immunization with the self-antigen covalently linked to an immunogenic foreign protein antigen, class-switched antibodies against the self-antigen can be produced (7).
We hypothesized that breakdown of B-cell tolerance is initiated by the simultaneous uptake of an autoantigen and a viral antigen by B cells from infected parenchymal cells. Antigen capture from cell membranes differs significantly from capture of soluble antigen: Membrane-bound antigens are multivalent, increasing the binding avidity in comparison with a monovalent antigen in solution (8); moreover, membrane-bound antigens exist in association with other protein and lipid components of the membrane, so that sometimes these bystander molecules can be cocaptured with the cognate antigen (9). We speculated that if such bystander antigens were processed and presented to T cells, it would circumvent the antigen specificity of T-cell help. Concretely, we hypothesize that if an autoreactive B cell binds a cognate self-antigen on the surface of a virus-infected cell, it can capture both self and neighboring viral antigens and, by presenting peptides from the viral antigen, can obtain T-cell help from antiviral T cells, leading to the production of antibodies against the self-antigen.
We tested this hypothesis using adherent cells that express the CNS-restricted membrane protein MOG as a model self-antigen, influenza hemagglutinin (HA) as a model viral antigen, and transgenic mouse B and T cells specific for each antigen.
Results
Capture of Cognate Antigen from Membrane Is Rapid and Robust.
Capture of cognate antigen from membrane has been examined in molecular detail (10, 11), generally using isolated membrane preparations. We examined the capture of cognate antigen from membranes of live cells by IgHMOG transgenic B cells, whose BCR recognizes the extracellular domain of MOG (12). When IgHMOG B cells were exposed to adherent HEK cells that express a MOG-GFP fusion, GFP capture was detected in the B cells by flow cytometry as soon as 1 min after contact and continued to increase for more than 1 h (Fig. 1 A–C and Movie S1). Capture was paralleled by loss of surface IgM, indicating internalization of the BCR–antigen complex (Fig. 1 A and B). Immunolabeling of cocultures showed that captured antigen and IgM associate with LAMP1-immunoreactive structures within the B cell, presumably lysosomes (Fig. 1 D and E). Initially these structures are seen only at the interface of B cell and antigen-expressing HEK cell (Movie S2), but upon prolonged interaction, they distribute throughout the B cell (Fig. 1 D and E and Movie S3). After extended interaction, the majority of the Ig colocalizes with antigen (Movie S3).
Membrane Antigen Capture Renders B Cells Highly Antigenic for T Cells.
We exposed IgHMOG B cells for 8, 12, or 20 h to adherent TE cells that express MOG (TE MOG) and examined expression of activation markers by flow cytometry. TE cells are more strongly adherent than HEK cells, facilitating their separation from B cells, but less efficiently transfected. In our hands, the type of antigen-presenting cell has no obvious influence on B-cell antigen capture. We compared these membrane antigen-capturing B cells with identical B cells exposed to non–antigen-expressing TE cells or to soluble MOG protein or to an IgM-crosslinking antibody. Loss of surface IgM was similar for B cells exposed to soluble or membrane-expressed antigen, but up-regulation of the activation markers CD69 and CD25 was far greater on the B cells exposed to membrane antigen (Fig. 2A). Up-regulation of class II MHC and CD86 was similar for the three kinds of BCR stimulation (Fig. 2A). Elevated class II expression was maintained longer after membrane capture than after other forms of BCR stimulation, but this effect was not statistically significant at the time points studied.
We next examined the presentation of captured membrane antigens to T cells by coculturing IgHMOG B cells (MHC class II allotype I-Ab) with TE MOG cells and then retrieving and coculturing them with 2D2 T cells, which recognize MOG 35–55 in the context of I-Ab (13). The 2D2 T cells exposed to IgHMOG B cells after membrane capture proliferated more strongly than those cocultured with naive B cells in the presence of a high concentration of cognate peptide (Fig. 2 B and C). Soluble MOG protein was no more effective than peptide (Fig. 2C). Neither B cells exposed to culture supernatants from antigen-expressing cells nor to TE cells that did not express antigen stimulated any proliferation. This rules out involvement of secreted soluble antigen or antigen-independent properties of the TE cells (Fig. 2C). Rather, it appears that the act of antigen capture renders the capturing B cell highly stimulatory for T cells.
To test this interpretation, we assessed the stimulatory properties of B cells after membrane capture of antigens that were irrelevant for the responding T cell, with or without additional peptide that matches the T-cell specifitiy. We exposed HA-specific FluBI B cells (I-Ab) to TE cells stably transfected with HA (TE HA) and then retrieved and cocultured these B cells with 2D2 T cells in the presence or absence of exogenous MOG 35–55 peptide (Fig. 2D). Without additional peptide, FluBI B cells stimulated no proliferation of 2D2 T cells, whether or not the B cells had previously encountered HA. With added peptide, even antigen-naive FluBI B cells stimulated T-cell proliferation but much less than B cells that had been previously activated by membrane HA capture (Fig. 2D). The enhanced ability of B cells after membrane capture to stimulate T-cell proliferation may thus be due to the high level of activation of B cells and the concomitant increase in costimulatory ligands (Fig. 2A).
We also measured 2D2 T-cell proliferation in response to MOG-specific B cells exposed to the same TE cells with or without peptide (Fig. 2D). Again, preexposure to membrane-expressed MOG rendered the B cells more stimulatory for the T cells than pulsing with peptide, whereas the presence of HA had no effect. Providing the antigen in a form recognizable by the BCR—that is, soluble MOG 1–125 protein—resulted in only slightly greater stimulation of T-cell proliferation than pulsing with MOG 35–55 peptide, and IgHMOG B cells were only slightly better in inducing 2D2 proliferation after capture of MOG 1–125 protein compared with FluBI B cells, which must take up the protein via a BCR-independent route. Most strikingly, FluBI cells exposed to TE cells that express both HA and MOG stimulated the proliferation of MOG-specific T cells, without the addition of exogenous MOG peptide. This implies that MOG had been cocaptured with HA and processed and presented.
Cocaptured, Noncognate Antigen Is Presented and Can Qualify B Cells for T-Cell Help.
To visualize the capture of noncognate, “bystander” antigen, we generated an adherent HEK cell line stably cotransfected with MOG-GFP and HA (HEK HA MOG-GFP). We cocultured these cells with IgHMOG B cells or with FluBI B cells. Capture of MOG-GFP by IgHMOG B cells followed similar kinetics with or without coexpression of HA, but MOG-GFP capture by FluBI B cells was dependent on HA (Fig. 3A). This bystander cocapture was as rapid as cognate capture, being observable after 3 min of contact, but quantitatively less. Not all antigens we examined were cocaptured. For example, when FluBI B cells were exposed to TE cells that express HA, MOG-GFP, and mOVA-Cherry, the MOG-GFP is cocaptured but the mOVA-cherry is not (Fig. 3B).
Ig-bound antigens may be more efficiently presented to T cells than other endocytosed cargo (14–16). To address whether coacquired membrane antigens were processed and presented on MHC class II, we used TE cell lines stably transfected with MOG and HA or with HA alone. Because WSN/33 HA-specific, class II-restricted transgenic T cells were not available, we added a carboxy terminal fusion to the HA including amino acids 323–339 of ovalbumin (OVA), a peptide recognized by OT-II T cells in the context of I-Ab. IgHMOG B cells were exposed to TE HA-OVA or TE MOG HA-OVA for 3 h and then retrieved and cocultured with OT-II T cells for 4 d. T-cell proliferation and activation were assessed by flow cytometry of Cell Trace Violet (CTV) dilution and CD25 immunofluorescence, respectively. The results from this model were consistent with the degree of cocapture observed previously. After exposure to TE MOG HA-OVA, IgHMOG B cells stimulated robust proliferation in OT-II T cells, and this was dependent on MOG (Fig. 4 A and B). The increase in CD25 expression was not as great as in the cognate capture condition (Fig. 4A), and the percentage of proliferated T cells was also lower (Fig. 4B). We also saw secretion of IFN-γ, IL-2, and IL-4 in the interaction between B cells presenting a cocaptured antigen and T cells responding to that antigen, albeit less than in the cognate capture condition (Fig. 4C). Presentation of the noncognate antigen is dependent on cocapture, because mOVA, which contains the OT-II epitope but is not cocaptured with HA or with MOG (Fig. 3B), is also not presented to OT-II T cells by IgHMOG or FluBI B cells after exposure to TE MOG mOVA (Fig. 4D). To be certain that this result was not due to inadequate expression of the mOVA protein at the cell membrane, we confirmed the accessibility of extracellular, membrane-bound OVA in live TE MOG mOVA cells (Fig. 4E).
To test whether cocaptured antigen would qualify B cells for T-cell help, we used the same combination of model antigens—that is, IgHMOG B cells capturing antigen from TE cells expressing both MOG and HA-OVA—but extended the subsequent coculture of IgHMOG B cells with OT-II T cells to 7 d. To exclude the involvement of BCR-independent antigen uptake and the possibility that the mere fact of capturing antigen stimulates antibody production, we included negative controls of IgHMOG B cells interacting with TE HA-OVA or with TE MOG HA. As a positive control, another cell line was established that stably expresses MOG fused to the OT-II OVA epitope (TE MOG-OVA). We exposed the IgHMOG B cells to the TE cells expressing the different antigen combinations, retrieved and cocultured them with OT-II T cells, and measured anti-MOG antibodies in the culture supernatants. Omitting the T cells, the OVA epitope, or MOG, no antibodies were detected. When OT-II T cells were present and the OVA epitope was included in the B-cell cognate antigen, antibody production was robust. We clearly detected antibodies also when the OVA epitope was present on the HA antigen (Fig. 5A). Autoreactive B cells that present cocaptured viral antigen can thus be triggered to produce autoantibodies by unrelated antiviral T cells. To test whether cocaptured antigen could mediate T-cell help in an in vivo setting, we exposed IgHMOG B cells to adherent cells expressing the same four combinations of antigens and adoptively transferred them into Rag −/− mice, together with OT-II T cells. Two weeks later, the mice were killed and anti-MOG antibodies in the serum were measured using an IgG2a-specific secondary antibody. Results mirrored those obtained in vitro: Antibodies were clearly produced in the cocapture condition (antigenic cells coexpressing MOG and HA-OVA)—at a lower level than in the cognate capture paradigm (cells expressing MOG-OVA) but well above the baseline level (Fig. 5B). IgG2a production in the two negative control conditions (cells expressing either HA-OVA alone or MOG and HA) was not significantly different from baseline.
Discussion
Capture of antigen from membranes represents an alternative way of collecting antigen for B cells. It leads to strong activation of the B cell and robust antigen presentation. We show that membrane capture carries the risk that other antigens than the cognate one are cocaptured via the BCR, with two potentially pathological consequences: (i) Antiviral B cells acquire autoantigens together with the viral antigen and activate autoreactive T cells, and (ii) autoreactive B cells acquire viral antigens together with the autoantigen and get T-cell help from antiviral T cells to produce autoantibodies (Fig. 5C). We provide evidence that both consequences can occur.
It is clear from our results that not all combinations of antigen, although present in the same membrane, will be cocaptured. The absence of significant cocapture of the membrane–OVA fusion protein indicates that the phenomenon does not involve wholesale capture of large fragments of membrane and is likely to be limited to a subset of protein antigens that either share some particular localization in the membrane or else have some direct interaction. One possibility, for example, is that the interaction we observe here depends on the interaction between sialic acid residues on the MOG protein and the sialic acid-binding domain of the HA (17). This would limit the phenomenon to the set of sialated proteins, which includes much but not all of the membrane proteome (18). A major function of viral glycoproteins is attachment to host cell membranes, and therefore, the likelihood that viral proteins bind to the extracellular domains of membrane proteins is high.
A limitation of our study is that antigen capture takes place in vitro. Experimentally, this enables us to control the coexpression of antigens, and to be sure that they are captured directly by B cells rather than by some third cell type, but begs the question of how and where B cells capture and cocapture antigen in vivo. A large body of work has demonstrated that soluble antigens and fluid-borne viral particles are trapped and offered to B cells in the secondary lymphoid tissue by specialized cells including subcapsular macrophages and follicular dendritic cells (19). However, we envisage that cocapture events relevant to autoimmunity are more likely to occur during direct capture of viral antigen from infected cells, which is likely to occur during the B-cell infiltration of infected tissues that is seen during the acute response to virus (20).
The generation of autoantibodies via the cocapture mechanism is likely to be limited in several parameters. First, it will only occur during infections by viruses that encode abundant membrane proteins—that is, enveloped viruses. Second, autoantigens are limited to membrane proteins with an exposed extracellular domain. Third, the availability of nonanergised autoreactive B cells will be greatest for antigens that are not expressed in the bone marrow and particularly for antigens whose expression is limited to tissues that are not patrolled extensively by B cells under normal (i.e., noninflamed, noninfected) conditions, thereby avoiding the mechanisms of peripheral tolerance that are known to be triggered by exposure to self-antigen in the absence of cognate T-cell help (21). These limitations might explain why this phenomenon rarely translates into the infection-associated autoimmunity seen in clinics. Nevertheless this mechanism represents an important deviation from a fundamental principle of immunology that has stood up well since its formulation in 1969: that antibody secretion by a B cell depends on an interaction with a T cell recognizing the same antigen (22). We envisage that this and further study of the phenomenon will lead to significant modifications in the understanding of B-cell biology, autoimmunity, and tolerance.
Materials and Methods
Methods are described in detail in SI Materials and Methods. Cell lines are described in Table S1, primary immune cells are described in Table S2, and abbreviations used in the text are explained in Table S3.
Table S1.
Cell line | Transfected antigen | Source | Antibody used to verify surface expression |
TE 0 | No added antigen | ATCC CRL-8805 | |
TE MOG | MOG—that is, native MOG from Rattus rattus | NM_022668.2 PMID: 10428054 | 8.18C5 |
TE HA | HA—that is, native hemagglutinin from influenza A/WSN/33 | ACF54598.1 | FluBI mouse serum |
HEK | No added antigen | ATCC CRL-1573 | |
HEK MOG-GFP | MOG amino acids 1–204 fused to GFP | 8.18C5 | |
HEK HA MOG-GFP | HA | FluBI mouse serum | |
MOG amino acids 1–204 fused to GFP | 8.18C5 | ||
TE MOG-GFP | MOG amino acids 1–204 fused to GFP | 8.18C5 | |
TE MOG HA | MOG | 8.18C5 | |
HA | FluBI mouse serum | ||
TE mOVA | mOVA—a fusion protein comprising the signal peptide from H-2 Kb, the full sequence of chicken OVA, and the transmembrane domain of H-2 Db, which results in extracellular membrane expression | pODpCAGGS PMID: 14525595 | AB1225 |
TE MOG mOVA | MOG | 8.18C5 | |
mOVA | AB1225 | ||
TE MOG-OVA | MOG amino acids 1–204 fused to full-length chicken OVA | 8.18C5 | |
TE HA-OVA | HA-OVA—that is, A/WSN/33 HA fused to amino acids 312–345 of chicken OVA (this includes the epitope recognized by OT-II T cells) | FluBI mouse serum | |
TE MOG HA-OVA | MOG | 8.18C5 | |
HA-OVA | FluBI mouse serum |
Table S2.
Name | Properties | Source |
IgHMOG | Transgenic mouse line whose B cells express a BCR and secrete antibodies that bind an epitope in the extracellular domain (amino acids 1–125) of MOG | Guru Krishnamoorthy and Hartmut Wekerle, Max-Planck-Institut für Neurobiologie, Martinsried, Germany |
FluBI | Transgenic mouse line whose B cells express a BCR and secrete antibodies that bind an epitope in the extracellular domain of HA from influenza A/WSN/33 | Stephanie Dougan and Hidde Ploegh, Whitehead Institute, Cambridge, MA |
Wild type | “Wild type”—that is, nontransgenic B cells were derived from C57BL/6 mice, which share the same MHC class II allotype I-Ab as the other mice in the study | Jackson 000664 C57BL/6J |
2D2 | Transgenic mouse line whose CD4+, MHC class II-restricted T cells recognize MOG 35–55 in the context of I-Ab | Guru Krishnamoorthy and Hartmut Wekerle, or Jackson, C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J |
OT-II | Transgenic mouse line whose CD4+, MHC class II-restricted T cells recognize chicken OVA 323–339 in the context of I-Ab | Ed Palmer, Basel, or Jackson B6.Cg-Tg(TcraTcrb)425Cbn/J |
Table S3.
Abbreviation | Full name | Relevance |
ADEM | Acute disseminated encephalomyelitis | Autoimmune neurological condition characterized by the presence of serum autoantibodies and sometimes preceded by infections |
BCR | B-cell receptor | Surface recptor expressed by B cells, whose specificity is identical to the specificity of antibodies produced by that B cell |
Cherry | A variant of red fluorescent protein | |
CNS | Central nervous system | The brain and spinal cord, the physiological site of MOG expression |
GFP | Green fluorescent protein | |
GMF | Geometric mean fluorescence | Measure of central tendency in fluorescent flow cytometry |
HA | Hemagglutinin | The major envelope glycoprotein of influenza viruses, expressed on the plasma membrane of infected cells, and targeted by the anti-influenza B-cell response |
IgG | IgG | The class of Ig (BCR or antibody) expressed by class-switched B cells |
IgG 2a | IgG subclass 2a | A subclass of IgG, the production of which is particularly dependent on T-cell help |
IgM | IgM | The class of Ig (BCR or antibody) expressed by naive B cells |
LAMP1 | Lysosome-associated membrane protein 1 | Protein localized predominantly in lysosomal membranes and used here as a subcellular marker of lysosomes |
MHCII | Major histocompatibility complex, class II | Surface receptor expressed by antigen-presenting cells such as B cells and macrophages, which presents antigen fragments to T cells, thereby mediating T-cell antigen recognition |
MOG | Myelin oligodendrocyte glycoprotein | CNS-restricted cell-surface protein, autoantibodies against which are found in certain autoimmune conditions |
OVA | Ovalbumin | Protein found in chicken egg white, containing the experimental T-cell epitope OVA 323–339 |
PE | Phycoerythrin | Red protein–pigment complex fluorochrome used in flow cytometry |
TCR | T-cell receptor | Surface receptor expressed by T cells, which recognizes a particular combination of antigen-derived peptide (e.g., MOG amino acids 35–55) and its cognate MHC molecule (I-Ab in all of the experiments in this study) |
Mice and Primary Immune Cells.
C57BL/6 and Rag −/− mice were bred in the University of Basel Mouse Core Facility. Tg(TcraTcrb)425Cbn (OT-II) mice on a Rag2−/− background were a kind gift from Ed Palmer, University of Basel, Basel, Switzerland. FluBI mice (23) were bred from founder members provided by Stephanie Dougan and Hidde Ploegh, Whitehead Institute, Cambridge, MA. IgHMOG (ref. 12; also known as Th B cells) and C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (2D2) mice (13) were bred from founder members provided by Guru Krishnamoorthy and Hartmut Wekerle, Max-Planck-Institut für Neurobiologie, Martinsried, Germany. Primary immune cells were obtained from spleens by mechanical disruption and brief settlement to remove tissue fragments. B cells and CD4-positive T cells were obtained by negative selection using biotinylated antibodies and magnetic beads from Miltenyi. All procedures involving animals were considered and authorized by the Cantonal Tierversuchskommission.
Anti-MOG Antibody Assay.
Anti-MOG antibodies were measured in sera and in culture supernatants by flow cytometry as previously described (3). Supernatants were mixed with two volumes of reporter cell suspension in PBS containing 2% FCS by volume and 1 g/L of sodium azide on ice. The reporter cells include equal numbers of unlabeled TE MOG cells and CTV-labeled TE 0 cells. After 30 min on ice, the cells are washed, and antibodies adhering to the TE MOG cells are detected with Alexa 647 anti-mouse IgG or PerCP-conjugated anti-IgG2a secondary antibodies (both from Jackson Immunoresearch) and measured by flow cytometry. TE 0 and TE MOG populations are then separated by CTV label, and the ratio of geometric mean fluorescence intensities between TE MOG:TE 0 indicates the abundance of antibody in the supernatant.
Statistics.
Geometric mean fluorescence intensities of activation markers on B cells were analyzed by two-way analysis of variance (time versus condition) and the effect of condition by one-way analysis of variance followed by Dunnett’s Multiple Comparison Test to compare each of the conditions against “no stimulation.” T-cell proliferation data (proportions of cells in the CTV-low gate) and anti-MOG Ig levels in sera were analyzed by one-way analysis of variance followed by Dunnett’s test. Anti-MOG IgG levels in culture supernantants, expressed as ratios of geometric mean immunofluorescence TE MOG:TE 0, were analyzed by two-way analysis of variance (presence of T cells versus antigen condition), revealing a strong interaction, with an effect of condition limited to the T cells present condition. The Kruskal–Wallis test was therefore used to assess the effect of antigen condition, and Dunn’s Multiple Comparison Test was used to compare each of the conditions with the T cells absent condition.
SI Materials and Methods
Mice and Primary Immune Cells.
A full list of primary immune cells used in the study is presented in Table S2. C57BL/6 and Rag −/− mice were bred in the University of Basel Mouse Core Facility. Tg(TcraTcrb)425Cbn (OT-II) mice on a Rag2−/− background were a kind gift from Ed Palmer, University of Basel. FluBI mice (23) were bred from founder members provided by Stephanie Dougan and Hidde Ploegh, Whitehead Institute, Cambridge, MA. IgHMOG (ref. 12; also known as Th B cells) and 2D2 mice (13) were bred from founder members provided by Guru Krishnamoorthy and Hartmut Wekerle, Max-Planck-Institut für Neurobiologie, Martinsried, Germany. Primary immune cells were obtained from spleens by mechanical disruption followed by brief settlement under gravity to remove tissue fragments. B cells and CD4-positive T cells were obtained by negative selection using biotinylated antibodies and magnetic beads from Miltenyi (Pan B Cell Isolation Kit II, mouse 130–104-443, and CD4-positive T Cell Isolation Kit, mouse, 130–104-454). When higher purity of B cells was required, for example for the T-cell proliferation assays, the splenocytes were first predepleted with anti-CD43 beads (Miltenyi 130–049-801) before following the manufacturer’s instructions for the negative selection kit.
Peptides, Proteins, Antibodies, and Vital Dyes.
MOG 35–55 peptide and MOG 1–125 recombinant protein were obtained from AnaSpec. AffiniPure F(ab')2 Fragment Goat Anti-Mouse IgM, µ Chain Specific 115–006-020 was from Jackson Immunoresearch, and FITC-conjugated anti-mouse IgMa was from BD Pharmingen. CTV and Cell Tracker Deep Red were from ThermoFisher.
Plasmids and Cell Lines.
A full list of antigen-expressing cells used in the study is presented in Table S1. The ORF encoding rat MOG was amplified with its STOP codon from pRSV-MOG and cloned into the blasticidin (Gibco) resistance-conferring pcDNA6.2C-EmGFP-DEST (Invitrogen) by gateway cloning, following the manufacturer’s instructions. An expression plasmid encoding A/WSN/33 influenza HA under hygromycin (Sigma Aldrich) selection was purchased from Sino Biological. Fusion constructs MOG-GFP, MOG-OVA, and HA-OVA were made by template-switching PCR and cloned by Ligation Independent Cloning into the PigLIC vector, which confers puromycin (Gibco) resistance. The mOVA construct was amplified from pODpCAGGS (24) (a kind gift from Marc Jenkins, University of Minnesota, Minneapolis) and cloned into PigLIC. Cells transfected with this construct express OVA at the cell surface, which can be detected by flow cytometry on living cells using a polyclonal rabbit anti-OVA antibody (Ab1225, Millipore). HEK 293 embryonic kidney cells and TE671 rhabdomyosarcoma cells (referred to as “TE cells” throughout the text) were obtained from ATCC (LGC). Cells were transfected by exposure to 2 μg/mL of plasmid DNA and 5 μg/mL of polyethylenimine in RPMI medium without serum for 4 h. Cells were cultured in complete medium [RPMI medium containing 10% (vol/vol) FCS, 100 units/mL of penicillin, and 100 μg/mL of streptomycin, all from Gibco] at 37 °C in 5% carbon dioxide. Cells resistant to the appropriate selective antibiotic were sorted by the Department of Biomedicine Flow Cytometry Core after labeling, as described below. Cells were tested for mycoplasma infection on arrival and subsequently (LookOut Mycoplasma PCR Detection Kit, Sigma).
Cell-Surface Antigen Confirmation and General Flow Cytometry.
For each cell line designed to express a cell membrane antigen, we verified expression at the establishment of the cell line and subsequently periodically checked the expression of the antigen by immunofluorescence flow cytometry (Table S1). Adherent cells were washed in PBS, trypsinized, resuspended in complete medium, washed in labeling buffer (PBS containing 2% FCS by volume and 1 g/l of sodium azide), incubated for 30 min on ice in primary antibody, washed again, incubated with fluorescent secondary antibodies, washed, and measured on a BD LSR Fortessa flow cytometer (BD Biosciences). Cells known to be positive and negative for the target antigen were labeled and measured in parallel each time. A typical result from such an experiment is shown in Fig. 4E. When flow cytometry results are shown as contour plots, the contour lines are spaced at 10%. Gating strategies for each figure are shown in Fig. S1 for each figure.
B-Cell Flow Cytometry.
IgHMOG B cells isolated by negative selection were cocultured with TE MOG or TE 0 cells for 8–20 h in complete medium at 37 °C in 5% carbon dioxide and then retrieved and labeled with the following antibodies before analysis as above: APC-Cy7 anti-B220 (clone RA3-6B2), PerCP-Cy5.5 anti-CD69 (clone H1.2F3), PE-Cy7 anti-CD86 (clone GL1), APC anti–I-A/I-E (clone M5/114.15.2, Biolegend), PE anti-CD25 (clone PC61.5), AlexaFluor488 donkey anti-mouse IgM (Jackson Immuoresearch), and FITC R35-95 rat IgG2a kappa isotype control. All antibodies were from BD Biosciences unless otherwise specified.
T-Cell Proliferation Assays.
B cells were exposed to antigen-expressing adherent cells in 25 cm2 flasks for 3 h and then retrieved, counted, and put into the wells of 96-well plates at 50,000 per well in complete medium supplemented with 50 μM 2-mercaptoethanol. T cells were labeled with 5 μM CTV in Hanks’ Balanced Salt Solution (Gibco) at 37 °C for 15 min and then washed thrice in complete medium, counted, and added to the B-cell wells at 25,000 per well. After 4 or 5 d, the cocultures were retrieved; labeled with anti-CD19, anti-B220, anti-CD4, and anti-CD25 (all from BD Biosciences); and analyzed by flow cytometry on a BD LSR Fortessa.
Fixed and Live Cell Microscopy.
For high-resolution immunolabeling, B cells were added to HEK MOG-GFP cells growing in chambered coverslips (Ibidi) at 37 °C and at various time points were fixed in ice-cold 4% phosphate-buffered paraformaldehyde for 20 min and then washed in PBS, blocked in PBS containing 5% normal goat serum and 0.02% TritonX, and and immunolabeled with rat anti-mouse LAMP1 (Southern Biotech), followed by Alexa 647-conjugated goat anti-mouse IgM and Rhodamine RedX-conjugated goat anti-rat antibodies, both from Jackson Immunoresearch. Images were aquired with a Nikon a1r in line-scanning mode with a 60×, 1.40 NA oil immersion objective using voxel dimensions set at approximately Nyquist sampling. Acquisition was controlled by Nikon Elements software, and the same software was used to create three-dimensional reconstructions and maximum intensity projections from the stacks of XY planes. Regions of interest were subsquently cropped, and when necessary to enhance visibility, brightness and contrast were increased using the Fiji distribution of ImageJ (25). For live cell imaging, a similar setup was used, but the B cells were prelabeled with Cell Tracker Deep Red (Invitrogen) following the manufacturer’s instructions, and without fixing the cells, the chambered coverslips with the cells growing in complete medium were placed into a humidified chamber on the microscope stage held at 37 °C and 5% carbon dioxide by an INU-TIZ-F1 controller (Tokai Hit). The pinhole was opened to 5.0 Airy units and other parameters (PMT voltages, voxel dimensions, etc.) optimized to minimize laser light exposure. Approximately one frame per minute was captured, and frames were assembled into movies with Nikon Elements software.
Adoptive Transfer.
CD4-positive OT-II cells were separated from mouse spleens as above, washed in PBS, resuspended in cold PBS, and injected intraperitoneally into Rag −/− mice at 1 million per mouse. One day later, IgHMOG B cells were isolated as above, exposed to antigen-expressing adherent cells in 75 cm2 flasks for 3 h, and then retrieved, washed in cold PBS, counted and resuspended in cold PBS, and injected intraperitoneally at 4 million cells per mouse. Two weeks later, mice were killed and blood was taken from the right atrium, refrigerated overnight, and then cetrifuged at 5,000 × g for 10 min. Sera were stored at –20 °C until antibody assay.
Anti-MOG Antibody Assay.
Anti-MOG antibodies were measured in sera and in culture supernatants by flow cytometry as previously described (3). Supernatants were mixed with two volumes of reporter cell suspension in PBS containing 2% FCS by volume and 1 g/L of sodium azide on ice. The reporter cells include equal numbers of unlabeled TE MOG cells and CTV-labeled TE 0 cells. After 30 min on ice, the cells are washed, and antibodies adhering to the TE MOG cells were detected with Alexa 647 anti-mouse IgG or PerCP-conjugated anti-IgG2a secondary antibodies (both from Jackson Immunoresearch) and measured by flow cytometry. TE 0 and TE MOG populations were then separated by CTV label, and the ratio of geometric mean fluorescence intensities between TE MOG and TE 0 indicated the abundance of antibody in the supernatant.
Statistics.
Geometric mean fluorescence intensities of activation markers on B cells were analyzed by two-way analysis of variance (time versus condition), and because an effect of condition but not of time was found, the effect of condition was examined by one-way analysis of variance followed by Dunnett’s Multiple Comparison Test to compare each of the conditions against “no stimulation.” T-cell proliferation data (proportions of cells in the CTV-low gate) and anti-MOG Ig levels in sera were analyzed by one-way analysis of variance followed by Dunnett’s test. Anti-MOG IgG levels in culture supernantants, expressed as ratios of geometric mean immunofluorescence TE MOG:TE 0, were analyzed by two-way analysis of variance (presence of T cells versus antigen condition), revealing a strong interaction, with an effect of condition limited to the T cells present condition. The Kruskal–Wallis test was therefore used to assess the effect of antigen condition, and Dunn’s Multiple Comparison Test was used to compare each of the conditions with the T cells absent condition.
Supplementary Material
Acknowledgments
We thank D. Merkler, A.- K. Pröbstel, E. Palmer, G. Krishnamoorthy, J. Lünemann, and I. Tsunoda for advice and A. Sylvain, T. Peyer, A.- C. Lecourt, and the staff of the microscopy and flow cytometry core facilities of the DBM for technical help. Funding was provided from Swiss National Science Foundation Grants 310030_149966 and an MUAM award from the Medical Faculty of the University of Basel.
Footnotes
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1614472114/-/DCSupplemental.
References
- 1.Jasti AK, et al. Guillain-Barré syndrome: Causes, immunopathogenic mechanisms and treatment. Expert Rev Clin Immunol. 2016;12(11):1175–1189. doi: 10.1080/1744666X.2016.1193006. [DOI] [PubMed] [Google Scholar]
- 2.Wang GF, Li W, Li K. Acute encephalopathy and encephalitis caused by influenza virus infection. Curr Opin Neurol. 2010;23(3):305–311. doi: 10.1097/wco.0b013e328338f6c9. [DOI] [PubMed] [Google Scholar]
- 3.Pröbstel AK, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77(6):580–588. doi: 10.1212/WNL.0b013e318228c0b1. [DOI] [PubMed] [Google Scholar]
- 4.Wardemann H, et al. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374–1377. doi: 10.1126/science.1086907. [DOI] [PubMed] [Google Scholar]
- 5.Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: What thymocytes see (and don’t see) Nat Rev Immunol. 2014;14(6):377–391. doi: 10.1038/nri3667. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Fulcher DA, et al. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med. 1996;183(5):2313–2328. [Google Scholar]
- 7.Steinhoff U, Burkhart C, Arnheiter H, Hengartner H, Zinkernagel R. Virus or a hapten-carrier complex can activate autoreactive B cells by providing linked T help. Eur J Immunol. 1994;24(3):773–776. doi: 10.1002/eji.1830240343. [DOI] [PubMed] [Google Scholar]
- 8.Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature. 2001;411(6836):489–494. doi: 10.1038/35078099. [DOI] [PubMed] [Google Scholar]
- 9.Suzuki K, Grigorova I, Phan TG, Kelly LM, Cyster JG. Visualizing B cell capture of cognate antigen from follicular dendritic cells. J Exp Med. 2009;206(7):1485–1493. doi: 10.1084/jem.20090209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Carrasco YR, Batista FD. B cell recognition of membrane-bound antigen: An exquisite way of sensing ligands. Curr Opin Immunol. 2006;18(3):286–291. doi: 10.1016/j.coi.2006.03.013. [DOI] [PubMed] [Google Scholar]
- 11.Natkanski E, et al. B cells use mechanical energy to discriminate antigen affinities. Science. 2013;340(6140):1587–1590. doi: 10.1126/science.1237572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Litzenburger T, et al. B lymphocytes producing demyelinating autoantibodies: Development and function in gene-targeted transgenic mice. J Exp Med. 1998;188(1):169–180. doi: 10.1084/jem.188.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bettelli E, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197(9):1073–1081. doi: 10.1084/jem.20021603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Drake L, McGovern-Brindisi EM, Drake JR. BCR ubiquitination controls BCR-mediated antigen processing and presentation. Blood. 2006;108(13):4086–4093. doi: 10.1182/blood-2006-05-025338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Zhang M, et al. Ubiquitinylation of Ig beta dictates the endocytic fate of the B cell antigen receptor. J Immunol. 2007;179(7):4435–4443. doi: 10.4049/jimmunol.179.7.4435. [DOI] [PubMed] [Google Scholar]
- 16.Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol. 1990;8:773–793. doi: 10.1146/annurev.iy.08.040190.004013. [DOI] [PubMed] [Google Scholar]
- 17.Xiong X, McCauley JW, Steinhauer DA. Receptor binding properties of the influenza virus hemagglutinin as a determinant of host range. Curr Top Microbiol Immunol. 2014;385:63–91. doi: 10.1007/82_2014_423. [DOI] [PubMed] [Google Scholar]
- 18.McDonald CA, Yang JY, Marathe V, Yen TY, Macher BA. Combining results from lectin affinity chromatography and glycocapture approaches substantially improves the coverage of the glycoproteome. Mol Cell Proteomics. 2009;8(2):287–301. doi: 10.1074/mcp.M800272-MCP200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Cyster JG. B cell follicles and antigen encounters of the third kind. Nat Immunol. 2010;11(11):989–996. doi: 10.1038/ni.1946. [DOI] [PubMed] [Google Scholar]
- 20.Rainey-Barger EK, et al. The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system. Brain Behav Immun. 2011;25(5):922–931. doi: 10.1016/j.bbi.2010.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Rathmell JC, et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature. 1995;376(6536):181–184. doi: 10.1038/376181a0. [DOI] [PubMed] [Google Scholar]
- 22.Rajewsky K, Schirrmacher V, Nase S, Jerne NK. The requirement of more than one antigenic determinant for immunogenicity. J Exp Med. 1969;129(6):1131–1143. doi: 10.1084/jem.129.6.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Dougan SK, et al. Antigen-specific B-cell receptor sensitizes B cells to infection by influenza virus. Nature. 2013;503(7476):406–409. doi: 10.1038/nature12637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ehst BD, Ingulli E, Jenkins MK. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am J Transplant. 2003;3(11):1355–1362. doi: 10.1046/j.1600-6135.2003.00246.x. [DOI] [PubMed] [Google Scholar]
- 25.Schindelin J, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–682. doi: 10.1038/nmeth.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.